These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8463315)

  • 1. Mutations in a zinc-binding domain of human insulin-degrading enzyme eliminate catalytic activity but not insulin binding.
    Gehm BD; Kuo WL; Perlman RK; Rosner MR
    J Biol Chem; 1993 Apr; 268(11):7943-8. PubMed ID: 8463315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of zinc ligands of the insulin-degrading enzyme.
    Perlman RK; Rosner MR
    J Biol Chem; 1994 Dec; 269(52):33140-5. PubMed ID: 7806544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional analysis of conserved residues in the active site of insulin-degrading enzyme.
    Perlman RK; Gehm BD; Kuo WL; Rosner MR
    J Biol Chem; 1993 Oct; 268(29):21538-44. PubMed ID: 8104941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of glutamate-169 as the third zinc-binding residue in proteinase III, a member of the family of insulin-degrading enzymes.
    Becker AB; Roth RA
    Biochem J; 1993 May; 292 ( Pt 1)(Pt 1):137-42. PubMed ID: 8099278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An unusual active site identified in a family of zinc metalloendopeptidases.
    Becker AB; Roth RA
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3835-9. PubMed ID: 1570301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-degrading enzyme does not require peroxisomal localization for insulin degradation.
    Chesneau V; Perlman RK; Li W; Keller GA; Rosner MR
    Endocrinology; 1997 Aug; 138(8):3444-51. PubMed ID: 9231799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Determinants of Substrate Specificity in Human Insulin-Degrading Enzyme.
    Stefanidis L; Fusco ND; Cooper SE; Smith-Carpenter JE; Alper BJ
    Biochemistry; 2018 Aug; 57(32):4903-4914. PubMed ID: 30004674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of insulin degradation: expression of an evolutionarily conserved insulin-degrading enzyme increases degradation via an intracellular pathway.
    Kuo WL; Gehm BD; Rosner MR
    Mol Endocrinol; 1991 Oct; 5(10):1467-76. PubMed ID: 1775131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of active site residues of insulin-degrading enzyme alters allosteric interactions.
    Song ES; Daily A; Fried MG; Juliano MA; Juliano L; Hersh LB
    J Biol Chem; 2005 May; 280(18):17701-6. PubMed ID: 15749695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.
    Malito E; Ralat LA; Manolopoulou M; Tsay JL; Wadlington NL; Tang WJ
    Biochemistry; 2008 Dec; 47(48):12822-34. PubMed ID: 18986166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of a catalytic zinc binding site in Escherichia coli L-threonine dehydrogenase by site-directed mutagenesis of cysteine-38.
    Johnson AR; Chen YW; Dekker EE
    Arch Biochem Biophys; 1998 Oct; 358(2):211-21. PubMed ID: 9784233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulysin: an allosteric enzyme as a target for Alzheimer's disease.
    Song ES; Hersh LB
    J Mol Neurosci; 2005; 25(3):201-6. PubMed ID: 15800373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of substrate-free human insulin-degrading enzyme (IDE) and biophysical analysis of ATP-induced conformational switch of IDE.
    Im H; Manolopoulou M; Malito E; Shen Y; Zhao J; Neant-Fery M; Sun CY; Meredith SC; Sisodia SS; Leissring MA; Tang WJ
    J Biol Chem; 2007 Aug; 282(35):25453-63. PubMed ID: 17613531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yeast as a tractable genetic system for functional studies of the insulin-degrading enzyme.
    Kim S; Lapham AN; Freedman CG; Reed TL; Schmidt WK
    J Biol Chem; 2005 Jul; 280(30):27481-90. PubMed ID: 15944156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of glutamic acid 646 as a zinc-coordinating residue in endopeptidase-24.11.
    Le Moual H; Devault A; Roques BP; Crine P; Boileau G
    J Biol Chem; 1991 Aug; 266(24):15670-4. PubMed ID: 1678740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism.
    Shen Y; Joachimiak A; Rosner MR; Tang WJ
    Nature; 2006 Oct; 443(7113):870-4. PubMed ID: 17051221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formation of insulin fragments by insulin-degrading enzyme: the role of zinc(II) and cystine bridges.
    Bellia F; Pietropaolo A; Grasso G
    J Mass Spectrom; 2013 Feb; 48(2):135-40. PubMed ID: 23378084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure, function, and regulation of insulin-degrading enzyme.
    Hulse RE; Ralat LA; Wei-Jen T
    Vitam Horm; 2009; 80():635-48. PubMed ID: 19251053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-directed mutagenesis of the active site glutamate in human matrilysin: investigation of its role in catalysis.
    Cha J; Auld DS
    Biochemistry; 1997 Dec; 36(50):16019-24. PubMed ID: 9398337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple allosteric sites are involved in the modulation of insulin-degrading-enzyme activity by somatostatin.
    Tundo GR; Di Muzio E; Ciaccio C; Sbardella D; Di Pierro D; Polticelli F; Coletta M; Marini S
    FEBS J; 2016 Oct; 283(20):3755-3770. PubMed ID: 27579517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.